drugset / Trial / NCT00787332
A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome
RandomizedParallel-groupOpen-labelPrevention
Summary
Compare Clinical Success and Costs in two Arms
Timeline
- Start
- 2008-09
- Primary completion
- 2009-12
- Completion
- 2009-12
Publications
- Boyce SW, Bandyk DF, Bartholomew JR, Frame JN, Rice L. A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT Study. Am J Ther. 2011 Jan;18(1):14-22. doi: 10.1097/MJT.0b013e3181f65503.
- Frame JN, Rice L, Bartholomew JR, Whelton A. Rationale and design of the PREVENT-HIT study: a randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis. Clin Ther. 2010 Apr;32(4):626-36. doi: 10.1016/j.clinthera.2010.04.012.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Argatroban | Small molecule | — | Intravenous |
| Subject | Desirudin | Protein / enzyme biologic | 15 mg | Subcutaneous |
| Subject | Desirudin | Protein / enzyme biologic | 30 mg | Subcutaneous |